PDF
Citation
Print
INTRODUCTION
Progression of hepatic fibrosis is a response of the liver to injury such as non-alcoholic steatohepatitis, alcohol abuse, toxins, and chronic viral infection. In the liver fibrosis, there is an excessive accumulation of extracellular matrix (ECM), in which hepatic stellate cells (HSCs) are considered the primary source of collagens and other ECM components [1,2]. During liver injury, HSCs interact with neighboring cell types to become activated HSCs through the stimulation of cytokines and growth factors, such as tumor necrosis factor alpha (TNF-α), platelet-derived growth factor (PDGF), and transforming growth factor-β (TGF-β), mostly derived from macrophages [2,3].
Conventionally, hepatic macrophages can be classified as classically pro-inflammatory macrophages (M1) or activated immunoregulatory macrophages (M2). Although phenotypic expression of macrophages in the liver is much more complicated, the population of macrophages during the early phase of injury that drives HSC activation is pro-inflammatory [2,4]. These activated hepatic macrophages initiate paracrine stimulation, followed by the perpetuation of HSCs, which is characterized by proliferation, contractility, fibrogenesis, altered matrix degradation, chemotaxis, and inflammatory signaling [2,3]. Therefore, the communication between HSCs and macrophages is the key driver of hepatic fibrogenesis.
Irisin, an exercise-induced myokine derived from the proteolytic cleavage of fibronectin III domain-containing protein 5 (FNDC5), was found to enhance the browning of white adipose tissue, consequently increasing thermogenesis as well as energy expenditure [5,6]. It was shown that irisin is involved in a variety of diseases, including obesity, diabetes, non-alcoholic fatty liver disease, carcinogenesis [7,8]. Moreover, there is some evidence supporting a potential protective role of irisin in cardiac, renal, hepatic, and pancreatic fibrosis [9-15]. More specifically, previous reports on liver fibrosis showed that irisin suppressed HSC activation and reduced ECM deposition [11,15]. However, during the crosstalk of HSCs and macrophages in hepatic fibrogenesis, which is also a crucial part of the pathophysiology of the disease, the role of irisin remains unclear. Therefore, this study was aimed to investigate the effects of irisin on the interaction between HSCs and macrophages, which was based on the treatment of conditioned media (CM) from lipopolysaccharide (LPS)-induced Tamm-Horsfall protein-1 (THP-1) macrophages on HSCs.
METHODS
Materials
The reagents used in the study were obtained from the following indicated suppliers: recombinant human/murine/rat irisin from PeproTech Inc. (#100-65, Cranbury, NJ, USA); LPS and phorbol 12-myristate 13-acetate (PMA) from Sigma-Aldrich Inc. (St. Louis, MO, USA); (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from BioPrince (#MT1036, Chuncheon, Korea), primary antibodies procured from Abcam Plc (Cambridge, UK): anti-α-smooth muscle actin (α-SMA; 1:1,000, ab5694), from Cell Signaling Technology, Inc. (Danvers, MA, USA): anti-protein kinase B (AKT) (1:1,000, #9272), anti-phospho-AKT (Ser473) (1:1,000, #4060), anti-extracellular signal-regulated kinase 1/2 (ERK1/2; 1:1,000, #9102), anti-phospho-ERK1/2 (Thr202/Tyr204) (1:1,000, #9101), anti-poly(ADP-ribose) polymerase (PARP; 1:1,000, #9542), anti-cleaved-PARP (Asp214) (1:1,000, #9541), from GeneTex Inc. (Irvine, CA, USA): anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 1:4,000, GT239), from Santa Cruz Biotechnology Inc. (Dallas, TX, USA): anti-tissue inhibitor of metalloproteinases-1 (TIMP-1) (1:1,000, sc-365905); second antibodies from Cell Signaling Technology Inc.: anti-rabbit immunoglobulin G (IgG), horseradish peroxidase (HRP)-linked (1:5,000, #7074), anti-mouse IgG, HRP-linked (1:5,000, #7076); culture media (Dulbecco’s modified Eagle’s medium [DMEM], Rosewell Park Memorial Institute [RPMI] 1640) from Welgene Inc. (Gyeongsan, Korea), fetal bovine serum (FBS) from Access Cell Culture (Vista, CA, USA), penicillin-streptomycin from Life Technologies (Carlsbad, CA, USA).
Cell culture
LX-2 cells were maintained in high glucose DMEM, supplemented with 100 mL/L FBS, 100,000 U/L penicillin, and 100 mg/L streptomycin at 37°C in a humidified 5% CO2 incubator. THP-1 cells, immortalized human monocytes, were purchased from Korean Type Culture Collection (KTCC, Seoul, Korea) and were maintained in RPMI 1640 medium, supplemented with 100 mL/L FBS, 100,000 U/L penicillin, and 100 mg/L streptomycin at 37°C in a humidified 5% CO2 incubator.
Cell treatment and conditioned medium preparation
Non-adherent monocytic THP-1 cells were seeded at a concentration of 3×105 cells/well in a 6-well culture plate for 24 hours. THP-1 cells were differentiated into adherent macrophages by using PMA 100 ng/mL for 24 hours. THP-1 macrophages were rested in a fresh RPMI medium for 48 hours. After that, the medium was changed to fresh RPMI with LPS 10 ng/mL for 12 hours to polarize THP-1 macrophages into the inflammatory M1 phenotype. Then, the CM was collected and was centrifuged at 12,000 ×g for 10 minutes at 4°C, then stored at –20°C for further experiments. LX-2 cells were seeded at a concentration of 3×105 cells/well in a 6-well culture plate for 24 hours. Then, LX-2 cells were treated with a mixture of 75% fresh DMEM and 25% CM from M1 macrophages (fresh RPMI medium was used instead of CM as the control group), with or without irisin 10 nM for 6 or 24 hours.
Proliferation assay
LX-2 cells were seeded at a concentration of 5×104 cells/well in a 24-well culture plate for 24 hours. The cells were then treated with the mixture of CM from M1 macrophages, with or without irisin 10 nM for 24 hours. After the treatment, LX-2 cells were incubated with fresh DMEM containing MTT 250 ng/mL for 3 hours. The reduced MTT dye was dissolved in isopropanol and then was transferred to a 96-well plate to measure the absorbance at 570 nm by using SpectraMax 190 Microplate Reader (Molecular Devices LLC., San Jose, CA, USA).
Migration assays
Wound healing migration assay
LX-2 cells were seeded at a concentration of 5×105 cells/well in a 6-well culture plate for 24 hours. When the confluence reached >90%, the cells were incubated with 1 μg/mL mitomycin C diluted in serum-free DMEM for 1 hour. Then, an injury line was made using a yellow tip, and the cell monolayer was washed twice with DMEM. The cells were subsequently incubated for 6 hours with the mixture of CM from M1 macrophages, with or without irisin 10 nM. Cell migration was observed and pictures of the injury line at 0 and 6 hours were taken via microscopy. The covered area was measured by using ImageJ version 1.8.0_112 64bit (U.S. National Institutes of Health, Bethesda, MD, USA) and was considered as representing the capability of cell migration.
Transwell migration assay
Transwell migration assay was performed using Transwell Permeable Supports (8.0 µm pore size, #3422, Corning, NY, USA) in a 24-well plate. The lower chambers of the plate wells were filled with the mixture of CM from M1 macrophages. Then, LX-2 cells (3×104 cells/insert) in 100 μL DMEM were plated into a transwell insert containing irisin 0 or 10 nM, followed by adding the transwell insert into the plate well and incubating for 6 hours. Subsequently, the migrated cells were fixed and stained with hematoxylin and eosin (H&E), and the migrated cells within nine separate fields of the membrane were counted under light microscopy at 200× magnification.
Cell contraction assay
The Collagen-based Contraction Assay Kit (#CBA-201, Cell Biolabs Inc., San Diego, CA, USA) was used to assess the contraction of LX-2 cells. The collagen lattice was created by mixing two parts of LX-2 cell suspension (1×106 cells/mL) and eight parts of cold collagen gel working solution. Following this, 0.5 mL of the cell-collagen mixture was distributed into a 24-well culture plate and was incubated at 37°C for 1 hour for complete collagen polymerization before adding 1 mL of culture medium over each gel layer. The stressed matrix was developed for 24 hours by keeping the cells in an incubator. The medium was replaced with the mixture of CM from M1 macrophages, with or without irisin 10 nM. Then, the collagen gels were gently released from the sides of the culture plate to start the contraction. Pictures of the gels were taken and the difference of the perimeters of these gels at 0 and 48 hours was measured by using ImageJ to represent the capability of cell contraction.
Western blotting
The proteins of cell lysates were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) before being transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). These membranes were blocked for 1 hour at room temperature with 5% non-fat dry milk in 1X Tris-buffered saline containing 0.5% Tween-20 (TBS-T), washed with TBS-T, then incubated with primary antibodies at 4°C overnight or for 48 hours. The membranes were then washed with TBS-T and were incubated with the appropriate horseradish peroxidase-conjugated secondary antibodies at room temperature for 80 minutes. Subsequently, the blot images were taken using ChemiDoc Imaging System (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Quantitative reverse transcription-polymerase chain reaction
Total RNA was extracted with AccuPrep Universal RNA Extraction Kit (Bioneer Corp., Daejeon, Korea), and then transcribed to cDNA with Maxime RT PreMix Kit (iNtRON Biotechnology Inc., Seongnam, Korea), according to the manufacturer’s instruction. Real-time polymerase chain reaction (PCR) analysis was performed by using Power SYBR Green PCR Master Mix (Life Technologies Ltd., Paisley, UK) on QuantStudio 6 Flex Real-Time PCR System (Life Technologies Holdings Pte Ltd, Singapore) with the primer sequences. The comparative Ct (ΔΔCt) method was used to evaluate the mRNA expressions of target genes with the Ct values of target genes normalized to GAPDH as the reference gene.
Statistical analyses
Data were presented as mean±standard error of the mean of three or more independent experiments. Differences between the treatment groups were evaluated using the Student’s t test with Microsoft Excel for Microsoft 365 MSO version 2109 Build 16.0.14430.20292 (Redmond, WA, USA) 64-bit. Differences were considered significant when P<0.05.
RESULTS
Effects of CM and irisin treatment on HSCs activation
The treatment of CM from M1 macrophages did not change the level of α-SMA regardless of irisin treatment for 6 hours (mRNA) or 24 hours (protein) (Fig. 1).
Effects of CM and irisin treatment on HSCs proliferation and contractility
LX-2 proliferation was enhanced by the treatment of CM from the M1 phenotype for 24 hours, which was attenuated by irisin 10 nM (Fig. 2A) in the MTT assay. In the gel contractility assay, CM from M1 macrophages significantly enhanced the contractility of LX-2 cells after 48 hours of treatment, which was reversed by irisin co-treatment (Fig. 2B, C).
Effects of CM and irisin treatment on the signaling pathway of hepatic stellate cells
The effect of irisin on the proliferation of LX-2 could be only related to a decrease in phosphorylation of AKT (Fig. 4A, B). Protein expression of TIMP-1 was enhanced with a 6-hour treatment of CM from M1 macrophages and was attenuated by co-treatment with irisin 10 nM (Fig. 4A-C). This treatment for 6 hours increased the mRNA expressions of TIMP-1, matrix metalloproteinase-9 (MMP-9), but decreased in matrix metalloproteinase-2 (MMP-2). In addition, co-treatment with irisin 10 nM reduced the expressions of TIMP-1 and MMP-9 but had no effect on MMP-2 (Fig. 4D).
Effects of CM and irisin treatment on M1 polarization of macrophages
We checked the effect of irsin on macrophage polarization. THP-1 M0 macrophages were polarized into M1 phenotype and treated with different concentration of irisin (10, 25, 50 nM). When irisin was treated during polarization into M1 phenotype, there was no difference in the expression of interleukin-1β and TNF-α (M1 markers). Therefore, irisin did not affect M1 polarization of macrophages (Fig. 5).
DISCUSSION
The findings of this study showed that CM from M1 macrophages could induce perpetuation of HSCs and that recombinant irisin effectively attenuated fibrotic response of HSCs to CM, implying a beneficial role of myokine irisin in liver fibrosis.
Liver fibrosis is a multifactorial and progressive condition in which HSCs are known as the key players. In the complex environment of the liver, HSCs interact with multiple cell types, of which macrophages (Kupffer cells and monocytederived macrophages) are predominant and are considered as important determinants in both the progression and resolution of liver fibrosis [1-3]. It was reported that macrophage depletion during liver injury attenuated fibrogenesis, while depletion during recovery diminished regression of fibrosis [16,17]. Hepatic macrophages get involved during liver fibrosis in several ways, such as regulation of inflammatory, fibrogenic cytokines, and chemokines, as well as MMPs, recruitment and infiltration of immune cells, and apoptosis of HSCs [2,3,18]. Immune modulation targeting hepatic macrophages has recently been considered a promising antifibrotic strategy [18,19].
The health benefits of exercise are well-known and the role of irisin in various conditions and diseases has been progressively explored [7,8]. Concerning macrophages, several studies reported that the inflammatory status of LPS-activated macrophages was attenuated after treatment with exogenous irisin [20-22]. Additionally, our confirmation showed that irisin suppressed the release of pro-inflammatory cytokines and inhibited the oxidative stress in LPS-induced macrophages (Supplemental Fig. S1). The beneficial role of irisin has also been documented based on the treatment of HSCs as mentioned earlier [11,15]. Considering the potential protective role of irisin in such a complex setting of liver fibrosis, we assessed the effects of irisin on the close relationship between HSCs and macrophages based on LX-2 treatment with CM of pro-inflammatory THP-1 macrophages. Previous studies using a co-culture or CM-treatment model have shown that activated macrophages induced activation of HSCs and that molecular mechanisms related to this communication have been increasingly investigated [17,23-26]. Herein, although CM from M1 macrophages did not induce fibrogenesis of HSCs, we observed a significant change in other properties of HSC perpetuation, including increased proliferation, migration, and contractility. In addition, treatment of recombinant irisin reduced these responses of HSCs to CM from M1 macrophages, suggesting that irisin could inhibit the activation of HSCs stimulated by macrophages.
Activation of PDGF signaling triggers several downstream pathways, such as phospholipase Cγ, phosphatidylinositol 3-kinase (PI3K)/AKT, the signal transducer and activator of transcription (STAT) and TGF-β that induces downstream SMAD proteins, and some mitogen-activated protein kinase (MAPK) pathways, such as ERK, p38, and c-jun N-terminal kinase (JNK). Regulation of these downstream signaling pathways results in proliferation, migration, fibrogenesis, and survival of HSCs [2,3,27,28]. Moreover, previous studies reported that irisin showed its effects mostly through regulating the downstream signaling pathway of MAPK. Irisin was also demonstrated to be a regulator in AMPK, PI3K/AKT, and STAT3/Snail signaling [29]. Specifically, irisin inhibited proliferation, migration, and invasion, as well as induced apoptosis in cancer cells by inhibiting the PI3K/AKT pathway or stimulating PARP cleavage [30]. Irisin increased the proliferation of human umbilical vein endothelial cells by promoting the ERK1/2 pathway [31]. Our findings showed that CM from M1 macrophages suppressed apoptosis of HSCs by inhibiting PARP cleavage, and increased proliferation and migration of HSCs by activating the AKT and ERK1/2 pathways. Additionally, irisin co-treatment reversed these effects by inhibiting only the AKT signaling pathway.
Besides chemoattractant molecules, early ECM degradation is the key element for activated HSC migration to injured sites, followed by ECM remodeling, in which MMPs and TIMPs are key drivers [3,4]. HSCs are the important source of TIMP-1 and TIMP-2; an increase in these inhibitors is associated with progressive fibrosis [32]. The expression of MMPs, particularly MMP-2 and MMP-9, is considered the key event to alter ECM and facilitate HSC migration [32,33]. The elevation of TIMP-1, MMP-2, MMP-9 in this study could be related to the increases in HSC migration induced by the CM from inflammatory macrophages. We also found that irisin co-treatment diminished HSCs migration and MMP-9, TIMP-1 expression, suggesting irisin acts through regulation of MMP-9 and TIMP-1.
Several human studies have shown the beneficial effect of exercise in patients with cirrhosis. In most studies, this benefit was demonstrated as an improvement in VO2 max or improvement in endurance as measured by the 6-minute walk test [34]. Future studies are needed to establish the safe and effective exercise regimens in patients with cirrhosis and research into the role of muscle function in liver cirrhosis remains limited by an ongoing poor understanding of its relationship with muscle function, myokines such as irisin and liver fibrosis
In the future, further confirmation and investigation into irisin receptors are needed to further elucidate the detailed molecular mechanism of irisin effects on liver fibrosis. Interestingly, a proposed receptor of irisin, αV integrin receptor, is one of the downstream pathways of TGF-β signaling [8,35].
In conclusion, irisin was found to suppress the perpetuation stage of HSC activation, particularly regarding HSC communication with macrophages. This supported evidence that irisin may have a favorable role in the reversal of liver fibrosis.
XML Download